Pharmaceuticals, Biotechnology and Life Sciences
The new safety data is from the ESCAPE-TRD Phase 3b study, which showed esketamine NS demonstrated a significant increase in…
J&J has answered allegations about its batch of vaccines that could not be used after ingredient issues.
NeuClone starts dosing NeuLara ustekinumab the first patients, a Johnson and Johnson’s Stelara biosimilar candidate, in a Phase I clinical…
The U.S. Food and Drug Administration (FDA) has approved Xarelto (rivaroxaban) for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalized acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding, Janssen said Monday in a press release.
FDA has approved Invokana (canagliflozin) to treat diabetic kidney disease (DKD) and reduce the risk of hospitalization for heart failure in patients with type 2 diabetes (T2D) and DKD, which is the only diabetes medicine indicated to slow the progression of diabetic nephropathy (also known as DKD) and reduce the risk of hospitalization for heart failure in patients with T2D and DKD.
The Janssen has filed for a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking first-in-class approval of guselkumab brand Tremfya, for the treatment of adult patients with active psoriatic arthritis (PsA), and expects to submit a marketing application to the European Medicines Agency seeking approval of TREMFYA as a treatment for PsA before the end of the year.
Johnson & Johnson has bought Auris Health, Inc. for about $3.4 billion in cash, with additional payments of up to $2.35 billion, in the aggregate, which may be payable upon reaching certain predetermined milestones, JJ said in a statement Monday.
Johnson & Johnson has received a binding offer from Platinum Equity, a private investment firm, to acquire its LifeScan business…
Johnson & Johnson’s Janssen has welcomed the news from Health Canada as it got approval to use Zytiga combined with prednisone…
Idorsia Ltd has made meaningful collaboration with industry leaders in the six and a half months since the demerger from…